Skip to content

Insider · CIK 0001879177

James Craig Nixon

director

Files at DUOT (DUOS TECHNOLOGIES GROUP, INC.). First filing Sep 22, 2026, latest Sep 22, 2026.

James Craig Nixon files SEC Form 4 as director at DUOT (DUOS TECHNOLOGIES GROUP, INC.). Since Sep 22, 2026, James Craig Nixon has reported 1 open-market buy worth $49k and 0 open-market sells worth $0, the latest filed on Sep 22, 2026.

A track record needs three past buys with six months of prices behind them; James Craig Nixon has 0, so none is measured yet.

The newest scored trade: bought $49k of DUOT on Sep 18, 2026, filed Sep 22, 2026, scored 33 (weak). In the last 12 months: 1 buy worth $49k and 0 sells worth $0.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 0
$49k bought, $0 sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

DUOT: DUOS TECHNOLOGIES GROUP, INC.

DUOTOct 9, 2026 · close 7.20

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
33Weak
DUOTbuy 2
DUOS TECHNOLOGIES GROUP, INC.
$49k
5,764 shares
+7%-

Transactions

Every row this insider has filed, 12 in all, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Sep 30, 2026DUOT
DUOS TECHNOLOGIES GROUP, INC.
AGrant or award
Common Stock, $0.001 par value
+2,099$8.93$19k86,6224 d ago
Sep 18, 2026DUOT
DUOS TECHNOLOGIES GROUP, INC.
POpen-market purchase
Common Stock, $0.001 par value
+2,857$8.50$24k81,61621 d ago
Sep 18, 2026DUOT
DUOS TECHNOLOGIES GROUP, INC.
POpen-market purchase
Common Stock, $0.001 par value
+2,907$8.60$25k84,52321 d ago
Mar 31, 2026DUOT
DUOS TECHNOLOGIES GROUP, INC.
AGrant or award
Common Stock, $0.001 par value
+3,735$6.69$25k77,203Apr 2, 2026
Dec 31, 2025DUOT
DUOS TECHNOLOGIES GROUP, INC.
AGrant or award
Common Stock, $0.001 par value
+2,185$11.44$25k63,468Feb 19, 2026
Dec 31, 2025DUOT
DUOS TECHNOLOGIES GROUP, INC.
AGrant or award
Common Stock, $0.001 par value
+10,000$11.44$114k73,468Feb 19, 2026
Dec 31, 2025DUOT
DUOS TECHNOLOGIES GROUP, INC.
AGrant or award
Common Stock, $0.001 par value
+2,185$11.44$25k63,468Jan 5, 2026
Jan 2, 2026DUOT
DUOS TECHNOLOGIES GROUP, INC.
AGrant or award
Common Stock, $0.001 par value
+10,000$10.80$108k73,468Jan 5, 2026
Sep 30, 2025DUOT
DUOS TECHNOLOGIES GROUP, INC.
AGrant or award
Common Stock, $0.001 par value
+2,018$7.43$15k61,283Oct 2, 2025
Jun 30, 2025DUOT
DUOS TECHNOLOGIES GROUP, INC.
AGrant or award
Common Stock, $0.001 par value
+2,032$7.38$15k59,265Jul 2, 2025
Mar 31, 2025DUOT
DUOS TECHNOLOGIES GROUP, INC.
AGrant or award
Common Stock, $0.001 par value
+2,808$5.34$15k57,233Apr 2, 2025
Dec 31, 2024DUOT
DUOS TECHNOLOGIES GROUP, INC.
AGrant or award
Common Stock, $0.001 par value
+2,112$5.92$13k54,425Jan 3, 2025

Questions about James Craig Nixon

Answered from the filings on this page, as of the latest one.

Is James Craig Nixon buying or selling?

In the last 12 months James Craig Nixon reported 1 open-market buy worth $49k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $49k of DUOT on Sep 18, 2026. Grants, option exercises and tax withholding are not counted.

How did James Craig Nixon's past buys perform?

Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James Craig Nixon has 0.

Where does James Craig Nixon file Form 4?

James Craig Nixon has filed Form 4 at DUOT (DUOS TECHNOLOGIES GROUP, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.